Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ozanimod - Celgene

Drug Profile

Ozanimod - Celgene

Alternative Names: Ozanimod-HCl; Ozanimod-hydrochloride; RPC-1063; RPC-1063-HCl

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Scripps Research Institute
  • Developer Celgene Corporation; Receptos
  • Class Anti-inflammatories; Antiulcers; Indenes; Nitriles; Oxadiazoles; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • Preregistration Multiple sclerosis
  • Phase III Crohn's disease; Ulcerative colitis

Most Recent Events

  • 25 Dec 2019 Celgene plans a phase I trial in healthy volunteers (PO) in July 2020(NCT04211558)
  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
  • 04 Oct 2019 Celgene initiates a phase I drug-drug interaction trial (In volunteers) in the US (PO) (NCT04149678)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top